Purpose: To assess the efficacy of fertility preservation (FP) and the impact of chemotherapy on the reproductive potential of Japanese patients with breast cancer. 
ductal invasion and most of these patients are likely to undergo adjuvant chemotherapy, with well-known gonadotoxic effects. 2 Anticancer drugs, such as alkylating agents, suppress ovarian function and frequently induce premature ovarian failure (POF). 3 In addition, when treatment requires anti-estrogenic agents, such as tamoxifen, for adjuvant treatment, the treatment can last for 5 years, resulting in severe infertility due to aging. 4 The survivors of cancer of reproductive age have high risks of infertility, making it very difficult to have a biological child after they have recovered from their cancer.
In the authors' centers, 140 patients with various forms of cancer have undergone fertility treatment and fertility preservation (FP) since
2003. In this study, the focus was on patients with breast cancer in order to assess the efficacy of FP, as well as the impact of chemotherapy on the reproductive potential of patients with breast cancer in the Japanese population.
| MATERIALS AND METHODS
A total of 62 patients with breast cancer visited the authors' cent- (n = 42) were divided into two groups, according to their treatment:
group A (patients with cancer who cryopreserved their oocytes and/ or embryos before cancer treatment for FP) and group B (patients with cancer who underwent infertility treatment after cancer treatment). All the group B patients were approved for infertility treatment by their oncologists. Group B was further divided into two subgroups:
group B1 (no chemotherapy for cancer treatment) and group B2 (postchemotherapy) in order to assess the effect of anticancer drugs on their ovarian reserve and IVF outcome. In this study, there was no patient with POF due to chemotherapy. 
| RESULTS
All the patients had breast cancer surgery. The patients agreed to preserve their fertility (group A) or to undergo fertility interventions (group B). All the group A patients underwent egg collection for FP before receiving any chemotherapy. In group A, the interval between the cancer operation and chemotherapy was 2.1 ± .7 months
(1-3 months). The average age at first admission was significantly lower in group A than in group B2 (35.19 ± 3.14 vs 40.50 ± 2.56 years old, P < .001), although the serum AMH levels were similar among the three groups ( Table 2 ). The numbers of collected oocytes and vitrified embryos were significantly larger in groups A and B1 than in group B2 (group A vs group B2: collected oocytes, 6.86 ± 5.62 vs 2.42 ± 2.54, P < .001; vitrified embryos, 2.24 ± 2.11 vs .24 ± .50, P < .002) (group B1 vs B2: collected oocytes, 5.76 ± 4.95 vs 2.42 ± 2.54, P < .01; vitrified embryos, 2.00 ± 2.83 vs 0.24 ± 0.50, P < .01) ( Table 2 ). There was a statistically significant difference in the serum peak estradiol (E2) levels between groups B1 and B2 (1211.10 ± 1017.97 vs 504.82 ± 423.82 pg/mL, P < .001) ( Table 2) , possibly derived from the ovarian reserve of the patients, and the presence or absence of letrozole between the groups (Table 1 ). The peak serum E2 levels tended to be lower in the cycles with letrozole than in the cycles without letrozole, although this was not statistically significant (Table 3) . The ratio of patients with a past history of irradiation and hormonal therapy for breast cancer was similar between groups B1 and B2 (Table 2) .
Also analyzed was the background of the pregnant patients. Nearly half (10/21) of the IVF patients who underwent an embryo transfer (ET) achieved a pregnancy, including the two patients in group A who underwent a vitrified-warmed ET (Table 4 ). All the pregnant women were nulligravida. It was of note that 70% (7/10) of those pregnant patients were pre-or without chemotherapy with the vitrifiedwarmed ET (six patients) or fresh ET (one patient). Among the pregnant women, the serum AMH was measured in seven cases: the average serum AMH level was 3.00 ± 2.41 ng/mL. There was no statistically significant difference in the AMH levels between the pregnant women without chemotherapy (five patients) and those after chemotherapy (two patients) (3.35 ± 2.70 vs 2.13 ± 1.92 ng/mL, P = .59). The miscarriage rate was 20% (2/10), two patients have an ongoing pregnancy, and six patients delivered healthy babies without complications (average birthweight: 3182 ± 345 g; birth height: 49.5 ± 2.1 cm).
Those patients who underwent oocyte cryopreservation have not yet returned to use their oocytes.
| DISCUSSION
To the best of the authors' knowledge, there has been no other study of the Japanese population that focuses on FP among the survivors of breast cancer and reports their outcomes of fertility interventions and pregnancy rates. Although the authors were unable to identify the precise cancer stage, regimen, or anticancer agent that was used for the patients in this study, the significance of preserving their fertility before chemotherapy appears to be remarkable, as chemotherapy significantly compromised the ovarian reserve, leading to poorer IVF outcomes ( Patients who did not vitrify embryos due to no fertilization or embryo development arrest;
b Letrozole was used in the estrogen receptor-positive patients in Group A. Letrozole was used in the patients who were estrogen receptor-positive and/or had a low ovarian reserve in groups B1 and B2.
T A B L E 1 Patient profile and modes of treatment group B2 (Table 2 ). This might be related in part to the younger age at admission of the FP patients (Table 2 ) and an absence of the possible detrimental effects of chemotherapy on the oocytes because both the group A and group B1 patients were never exposed to gonadotoxic ET, embryo transfer; FP, fertility preservation.
T A B L E 2 Clinical outcomes of in vitro fertilization

T A B L E 4 Pregnancy outcome after in vitro fertilization (IVF)
Although the number of studied women was limited, their pregnancy rate was relatively good, especially with FP (Table 4) . That might be related in part to the fact that 70% of the pregnant women had their embryos cryopreserved or had a fresh ET pre-or without chemotherapy. This indicates that, in patients with breast cancer, it is important to preserve their fertility before chemotherapy and then relatively good pregnancy rates are expected.
In a European registry study, 50% of the patients with cancer eventually had live births from their cryopreserved embryos. 3 It was speculated that though it is common to estimate the frozen embryo implantation potential with the use of data from the age-matched infertile population, it is possible that implantation rates in the cancer population could be higher because they are presumably fertile when their embryos are cryopreserved. Meanwhile, another study reported the use of the GnRH agonist, goserelin, for ovarian protection during adjuvant chemotherapy in hormone receptor-negative patients with breast cancer, leading to a better pregnancy rate, disease-free rate, and overall survival, compared to the chemotherapy-alone group, which could be promising for patients with breast cancer of reproductive age.
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There have been limited ways to preserve fertility in women: em- 
